Form 4 for SKYE Skye Bioscience, Inc.
Accepted 2021-12-16 00:00:00 ET · period of report 2021-12-14 · accession 0001516551-21-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-16 | 2021-12-14 | SKYE | Arsenault Kaitlyn Melanie | CFO | A - Grant | — | +1.00M | 1.00M | New | — |
| D | 2021-12-16 | 2021-12-14 | SKYE | Arsenault Kaitlyn Melanie | CFO | A - Grant | $0.00 | +1.77M | 1.77M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-14 | A | A | 1,000,000 | — | 1,000,000 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full. (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-14 | A | A | 1,770,000 | $0.00 | 1,770,000 | D | $0.06 · — to 2031-12-14 | 1,770,000 Common Stock | (F3) The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested. |